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• Progress reports HL078976-02, -03, and -04.
As a result of its investigation, UK recommended that the publication(s) listed above be retracted or corrected.
Specifically, ORI finds that Respondent:
• Falsely reported in Figure 14 and associated text in NIH grant applications R01 HL07897601 and -01A1 that experiments were performed to determine if endothelialspecific caveolin-1 null mice were protected from saturated fatty acid-induced atherosclerosis, when these mutant mice did not exist in the laboratory at the time; Dr. Smart also falsely reported the use of these mice in related progress reports R01 HL078976-02, -03, and -04 and in three (3) additional NIH grant applications: Figure 11 in R01 HL088150-01, Figure 11 in U54 CA116853, and Figure 9 in DK063025-01A2
• Falsified and/or fabricated images in NIH grant application R01 HL078976-01A1 by duplicating and altering bands in 14 Western blot images and one (1) RT-PCR image included in Figures 3, 6 , 11, 12, 13, 14, and 15; false Western blots were also included in the earlier version of the grant application R01 HL078976-01, Figures 3, 6 , 11, 13, and 14
• Falsified and/or fabricated Western blots and one (1) RNase protection assay by duplicating and altering bands in thirty-three (33) figures included in ten (10) published papers, one (1) submitted manuscript, and two (2) NIH grant applications. Specifically, false or fabricated images were included in:
< Figures 5 and 7, J. Biol. Chem. 277(7):4925-31, 2002 < Figure 4B , Am J. Physiol. Cell Physiol. 291(6): C1271-8, 2006 < Figures 2A, 3A, 6A, and 7A, Am J. Physiol. Cell Physiol. 294(1):C295-305, 2008 < Figures 3, 5, and 6, J. Lipid Res. 45:1444 -1449 , 2001 < Figure < Figures 1A and 5B, J. Biol. Chem. 280(33):29543-50, 2005 < Figures 1A, 2A /B, and 4A, J. Biol. Chem. 273:6525-6532, 1998 < Figure 1B , Am J. Physiol. Cell Physiol. 282:C935-46, 2002 < Figures 2A, 4 , 6B, 7, and 8 in a submitted manuscript < Figures 7A, 8A , 9A, and 10B in grant application HL093155-01 < Figures 4, 7, and 13 in grant application HL068509-01A1.
Dr. Smart has entered into a Voluntary Exclusion Agreement and has voluntarily agreed for a period of seven (7) years, beginning on October 23, 2012:
(1) To exclude himself from any contracting or subcontracting with any agency of the United States Government and from eligibility or involvement in nonprocurement programs of the United States Government referred to as ''covered transactions'' pursuant to HHS' Implementation (2 CFR part 376 et seq.) of OMB Guidelines to Agencies on Govermentwide Debarment and Suspension, 2 CFR part 180 (collectively the ''Debarment Regulations'');
(2) To exclude himself voluntarily from serving in any advisory capacity to PHS including, but not limited to, service on any PHS advisory committee, board, and/or peer review committee, or as a consultant; and (3) To request that the following publications be retracted or corrected: J. Biol. Chem. 277 (7): 4925-31, 2002; Am J. Physiol. Cell Physiol. 291(6):C1271-8, 2006 Am J. Physiol. Cell Physiol. 294(1):C295-305, 2008; J. Lipid Res. 42:1444 -1449 , 2001 J. Biol. Chem. 275:25595, 2000; J. Biol. Chem. 277(26):23525-33, 2002; Proc. Natl. Acad. Sci. USA 101(10):3450-5, 2004; J. Biol. Chem. 280(33):29543-50, 2005; J. Biol. Chem. 273:6525-6532, 1998; Am J. Physiol. Cell Physiol. 282:C935-46, 2002 .
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